Imagine a medicine that doesn't just cure a sick person, but also stops them from passing the disease to others. This project is testing a tasty, kid-friendly version of a drug called primaquine to make it easier for children to take. By doing this, they hope to break the chain of malaria transmission across three different African countries.
Low uptake of malaria transmission-blocking drugs due to a lack of child-friendly versions and safety fears regarding G6PD deficiency. This prevents the interruption of the malaria cycle in pediatric populations.
A real-life implementation study and a flavoured paediatric primaquine formulation designed for children.
If you are a drug manufacturer dealing with low adoption of adult-only malaria pills — this project developed a flavoured paediatric formulation that improves patient acceptability. This allows for the expansion of the target market to include children.
If you are a distributor dealing with the need for specialized antimalarial portfolios in Africa — this project provides real-life implementation data across 3 countries. This evidence helps in planning the rollout of transmission-blocking therapies.
If you are a consultancy dealing with outdated drug policies in malaria-endemic regions — this project generates clinical and sociological evidence to shift policy toward single low dose primaquine. This creates a roadmap for national health system updates.
Based on available project data, the specific cost or price of the flavoured primaquine is not mentioned.
The project builds on the 'Developing Paediatric Primaquine' project which aimed to prequalify formulations, suggesting a move toward industrial standards, though specific scale-up metrics are not provided.
Based on available project data, the IP and licensing details are not specified, though the project involves a consortium of 7 partners including the University of Strasbourg.
The project runs from 2023-04-01 to 2027-03-31, focusing on implementation studies and policy shifts during this window.
It is designed as a single low dose primaquine (SLDPQ) to be added to existing artemisinin-based combination therapies (ACTs).
The consortium is heavily academic, with 5 universities and 1 other organization, representing 86% of the partners. However, there is a strategic 14% industry presence (1 company), which is critical for translating the clinical findings into a commercial product. The geographic spread across 6 countries (including BF, BI, MG) ensures the results are validated across diverse epidemiological profiles.
Contact the University of Strasbourg regarding the implementation of paediatric primaquine.
Contact us to identify the industrial partner involved in the IMPRIMA consortium for licensing opportunities.
